At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 62 enrolled
Drug / intervention
Rozanolixizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis
In Brief
A Phase 3 clinical trial evaluating Rozanolixizumab for Generalized Myasthenia Gravis. Completed, enrolled 62 participants across 27 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Myasthenia Gravis
CountriesCanada, Georgia, Germany, Italy, Japan, Poland, Serbia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartApr 2023
Primary CompletionApr 2024
TodayJul 2026
First PostedJan 12, 2023
Enrollment StartApr 17, 2023
Primary CompletionApr 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.5 years ago
Interventions
Rozanolixizumabdrug
Rozanolixizumab self-administration via Syringe Driver or Manual Push.